Cancer prevention and screening in women

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Women aged 50 and older should be screened for breast cancer by mammography and clinical breast examination every 1 to 2 years. There is no clear evidence for benefit of screening in women younger than age 50. Women with a strong family history of breast cancer or breast and ovarian cancer should receive extensive counseling before making a decision about screening for mutations in BRCA1. There are no studies to guide recommendations for screening or prophylaxis for those women who choose screening and who carry a mutation. Screening for ovarian cancer by any modality for women of average risk is not recommended. Primary care providers should counsel women with a family history of ovarian cancer. Some women may benefit from genetic counseling and testing. Screening of high-risk women must be individualized between the provider and the patient, with the understanding that no screening modality has been shown to reduce mortality from this disease. Endometrial sampling is not useful in screening for endometrial cancer in an asymptomatic population. Endometrial sampling and the use of transvaginal ultrasound should be reserved for women with abnormal vaginal bleeding. Cervical cytology is an effective measure for cervical cancer prevention. Screening should begin at the onset of sexual activity and should be continued at least every 3 years up to age 65. Based on current studies, adjunctive tests such as HPV typing, cervicography, and Papnet are not useful screening tools and they are not recommended. Table 2 summarizes the incidence, risk factors, and US Preventive Services Task Force screening recommendations for the cancers discussed in this article.

Original languageEnglish (US)
Pages (from-to)15-26
Number of pages12
JournalPrimary Care - Clinics in Office Practice
Volume24
Issue number1
StatePublished - 1997

Fingerprint

Early Detection of Cancer
Ovarian Neoplasms
Breast Neoplasms
Mutation
Uterine Hemorrhage
Genetic Counseling
Genetic Testing
Advisory Committees
Mammography
Endometrial Neoplasms
Uterine Cervical Neoplasms
Sexual Behavior
Cell Biology
Counseling
Primary Health Care
Decision Making
Breast
Mortality
Incidence
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cancer prevention and screening in women. / Melnikow, Joy; Nuovo, James.

In: Primary Care - Clinics in Office Practice, Vol. 24, No. 1, 1997, p. 15-26.

Research output: Contribution to journalArticle

@article{35516e2a19bb4988a2007404deb2a106,
title = "Cancer prevention and screening in women",
abstract = "Women aged 50 and older should be screened for breast cancer by mammography and clinical breast examination every 1 to 2 years. There is no clear evidence for benefit of screening in women younger than age 50. Women with a strong family history of breast cancer or breast and ovarian cancer should receive extensive counseling before making a decision about screening for mutations in BRCA1. There are no studies to guide recommendations for screening or prophylaxis for those women who choose screening and who carry a mutation. Screening for ovarian cancer by any modality for women of average risk is not recommended. Primary care providers should counsel women with a family history of ovarian cancer. Some women may benefit from genetic counseling and testing. Screening of high-risk women must be individualized between the provider and the patient, with the understanding that no screening modality has been shown to reduce mortality from this disease. Endometrial sampling is not useful in screening for endometrial cancer in an asymptomatic population. Endometrial sampling and the use of transvaginal ultrasound should be reserved for women with abnormal vaginal bleeding. Cervical cytology is an effective measure for cervical cancer prevention. Screening should begin at the onset of sexual activity and should be continued at least every 3 years up to age 65. Based on current studies, adjunctive tests such as HPV typing, cervicography, and Papnet are not useful screening tools and they are not recommended. Table 2 summarizes the incidence, risk factors, and US Preventive Services Task Force screening recommendations for the cancers discussed in this article.",
author = "Joy Melnikow and James Nuovo",
year = "1997",
language = "English (US)",
volume = "24",
pages = "15--26",
journal = "Primary Care - Clinics in Office Practice",
issn = "0095-4543",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Cancer prevention and screening in women

AU - Melnikow, Joy

AU - Nuovo, James

PY - 1997

Y1 - 1997

N2 - Women aged 50 and older should be screened for breast cancer by mammography and clinical breast examination every 1 to 2 years. There is no clear evidence for benefit of screening in women younger than age 50. Women with a strong family history of breast cancer or breast and ovarian cancer should receive extensive counseling before making a decision about screening for mutations in BRCA1. There are no studies to guide recommendations for screening or prophylaxis for those women who choose screening and who carry a mutation. Screening for ovarian cancer by any modality for women of average risk is not recommended. Primary care providers should counsel women with a family history of ovarian cancer. Some women may benefit from genetic counseling and testing. Screening of high-risk women must be individualized between the provider and the patient, with the understanding that no screening modality has been shown to reduce mortality from this disease. Endometrial sampling is not useful in screening for endometrial cancer in an asymptomatic population. Endometrial sampling and the use of transvaginal ultrasound should be reserved for women with abnormal vaginal bleeding. Cervical cytology is an effective measure for cervical cancer prevention. Screening should begin at the onset of sexual activity and should be continued at least every 3 years up to age 65. Based on current studies, adjunctive tests such as HPV typing, cervicography, and Papnet are not useful screening tools and they are not recommended. Table 2 summarizes the incidence, risk factors, and US Preventive Services Task Force screening recommendations for the cancers discussed in this article.

AB - Women aged 50 and older should be screened for breast cancer by mammography and clinical breast examination every 1 to 2 years. There is no clear evidence for benefit of screening in women younger than age 50. Women with a strong family history of breast cancer or breast and ovarian cancer should receive extensive counseling before making a decision about screening for mutations in BRCA1. There are no studies to guide recommendations for screening or prophylaxis for those women who choose screening and who carry a mutation. Screening for ovarian cancer by any modality for women of average risk is not recommended. Primary care providers should counsel women with a family history of ovarian cancer. Some women may benefit from genetic counseling and testing. Screening of high-risk women must be individualized between the provider and the patient, with the understanding that no screening modality has been shown to reduce mortality from this disease. Endometrial sampling is not useful in screening for endometrial cancer in an asymptomatic population. Endometrial sampling and the use of transvaginal ultrasound should be reserved for women with abnormal vaginal bleeding. Cervical cytology is an effective measure for cervical cancer prevention. Screening should begin at the onset of sexual activity and should be continued at least every 3 years up to age 65. Based on current studies, adjunctive tests such as HPV typing, cervicography, and Papnet are not useful screening tools and they are not recommended. Table 2 summarizes the incidence, risk factors, and US Preventive Services Task Force screening recommendations for the cancers discussed in this article.

UR - http://www.scopus.com/inward/record.url?scp=0030936197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030936197&partnerID=8YFLogxK

M3 - Article

C2 - 9016727

AN - SCOPUS:0030936197

VL - 24

SP - 15

EP - 26

JO - Primary Care - Clinics in Office Practice

JF - Primary Care - Clinics in Office Practice

SN - 0095-4543

IS - 1

ER -